Feb. 20, 2008
PharmaIN announces award from National Institutes of Health to formulate potential new therapy to treat serious staphylococcal infections including MRSA
The multi-year, $400,000 award from NIH will advance early stage development of the Company’s novel formulation of lysostaphin.

Jun. 25, 2007
PharmaIN announces presentation of preclinical, type 1 diabetes data at 2007 Annual Scientific Sessions of the American Diabetes Association
Preclinical data suggests a long-acting formulation of native, human GLP-1 can promote the growth of insulin producing cells (beta cells) in a type 1 diabetes animal model.

Jun. 25, 2007
PharmaIN announces preclinical data on once weekly dosing, long-acting, natural GLP-1 formulation to treat type 2 diabetes
Preclinical data suggests native, human GLP-1 formulation can be dosed weekly and impact HbA1c levels dramatically in diabetic rat model of type 2 diabetes.

Apr. 23, 2007
PharmaIN announces $3 million award
from National Institute of Health
Significant award from NIH will advance Company's development of its novel therapy to treat type 1 diabetes.

Jan. 08, 2007
PharmaIN adds diabetes expert Riccardo Perfetti, MD, PhD
as new scientific advisor.
Experienced clinical and preclinical diabetes researcher to act in advisory role as Company plans clinical development for lead product, PGC GLP-1.

Jan. 04, 2007
PharmaIN receives first US patent for drug delivery technology.
First Company patent expands existing intellectual property estate with broad application toward improving pharmaceutical and biopharmaceutical products.